1. Lowering the viscosity of a high-concentration antibody solution by protein–polyelectrolyte complex
- Author
-
WeiLin Hsu, Keisuke Tsumura, Kentaro Shiraki, Masahiro Mimura, and Aiko Horiuchi
- Subjects
genetic structures ,Drug Compounding ,Bioengineering ,behavioral disciplines and activities ,Applied Microbiology and Biotechnology ,Protein Structure, Secondary ,chemistry.chemical_compound ,Viscosity ,Protein secondary structure ,Chromatography ,biology ,Antibodies, Monoclonal ,Glutamic acid ,Phosphate ,Polyelectrolytes ,Polyelectrolyte ,Solutions ,body regions ,nervous system ,chemistry ,Injection volume ,biology.protein ,Antibody ,Protein concentration ,psychological phenomena and processes ,Biotechnology - Abstract
High-concentration and low-viscosity antibody formulations are necessary when administering these solutions subcutaneously (SC) due to limitations on injection volume. Here we show a method to decrease the viscosity of monoclonal antibody solution by protein–polyelectrolyte complex (PPC) with poly- l -glutamic acid (polyE). The viscosity of omalizumab solutions was 90 cP at the concentration of 150 mg/mL. In the presence of 20–50 mM polyE, the viscosity of PPC solution of 150 mg/mL omalizumab dramatically decreased below 10 cP due to the formation of crowded solution. The crowded state of PPC, named aggregated PPC (A-PPC), contained water droplets with a diameter of 10 μm or larger with low antibody concentrations. In the presence of 60 mM or more polyE, the omalizumab solution was transparent with the viscosity of 40 cP or less, named soluble PPC (S-PPC). More importantly, the solutions of both A-PPC and S-PPC were fully redissolved by the addition of phosphate saline buffer confirmed by secondary structure, the amount of aggregates, and binding activity to antigen.
- Published
- 2022